ReviewNeuro-oncology advances
Safety of focused ultrasound in neuro-oncology: A summary of preclinical and clinical work.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focused ultrasound (FUS) has emerged as a promising technology in neuro-oncology with applications across both treatment and diagnosis of brain tumors. This review consolidates both preclinical and clinical evidence on the safety of the 2 primary FUS modalities, low-intensity focused ultrasound and high-intensity focused ultrasound. Safety data discussed has a particular emphasis on blood-brain barrier disruption, tissue effects, and neuroinflammatory responses. Although the field is advancing rapidly, comprehensive safety data remains fragmented across studies. With the current lack of standardization across FUS devices, treatment parameters, and microbubble characteristics, it is critical to summarize all currently available safety data to provide direction for the field. This review also aims to provide context for the vast amount of preclinical work into translatable data that can be used to justify and guide future clinical trials. Finally, the application of FUS in the pediatric population is discussed, along with special considerations and a current view on ongoing clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.